Futura Medical PLC, a consumer healthcare company specializing in the development and global commercialization of innovative sexual health products, is set to release its results for the year ended 31 December 2023 on Wednesday 10 April 2024. The company's Chief Executive Officer, James Barder, and Finance Director, Angela Hildreth, will conduct a live presentation for investors via the Investor Meet Company platform at 09:00 BST on the same day.
The presentation is open to all existing and potential shareholders, with the opportunity to submit questions beforehand through the Investor Meet Company dashboard or during the live event. Investors can register for the presentation through a provided link, and those already following Futura Medical PLC on the Investor Meet Company platform will automatically receive an invitation.
Futura Medical PLC is known for its development of innovative sexual health products, with its lead product, Eroxon, being a clinically proven treatment for Erectile Dysfunction (ED). Eroxon is a highly differentiated topical gel treatment for ED, available over the counter, and is designed to help men achieve an erection within ten minutes. The product addresses significant unmet needs in the ED market, as ED affects a substantial portion of the male population globally, with approximately half of all men over 40 experiencing ED and 25% of new diagnoses occurring in men under 40.
The company's core strength lies in its research, development, and commercialization of topically delivered gel formulations in sexual health products. Futura Medical PLC aims to address the substantial unmet needs in the ED market and provide innovative solutions for individuals affected by this condition.